Neurogene (NGNE) Total Non-Current Liabilities (2013 - 2026)
Neurogene (NGNE) posted Total Non-Current Liabilities of $25.4 million for Q1 2026, up 7.15% on a QoQ basis from $23.7 million in Q4 2025, and up 8.11% year-over-year from $23.5 million in Q1 2025.
Neurogene (NGNE) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Neurogene's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $25.4 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 8.11% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 8.11% YoY) and the FY2025 annual result came in at $23.7 million, down 3.94% from the prior year.
- Total Non-Current Liabilities was $25.4 million for Q1 2026 at Neurogene, up from $23.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $36.3 million in Q4 2023 and bottomed at $10.6 million in Q4 2022.
- A 5-year average of $24.2 million and a median of $24.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 241.66% — and 2024, when it slumped 32.22%.
- Neurogene's Total Non-Current Liabilities stood at $10.6 million in 2022, then jumped by 241.66% to $36.3 million in 2023, then slumped by 32.22% to $24.6 million in 2024, then dropped by 3.94% to $23.7 million in 2025, then rose by 7.15% to $25.4 million in 2026.
- Business Quant data shows NGNE's Total Non-Current Liabilities at $25.4 million in Q1 2026, $23.7 million in Q4 2025, and $22.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Neurogene | 17.50 Mn | 17.50 Mn | - | 25.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.36 Mn |
| Dec 31, 2025 | 23.67 Mn |
| Sep 30, 2025 | 22.24 Mn |
| Jun 30, 2025 | 24.01 Mn |
| Mar 31, 2025 | 23.46 Mn |
| Dec 31, 2024 | 24.64 Mn |
| Sep 30, 2024 | 26.66 Mn |
| Jun 30, 2024 | 24.76 Mn |
| Mar 31, 2024 | 24.37 Mn |
| Dec 31, 2023 | 36.35 Mn |
| Dec 31, 2022 | 10.64 Mn |
| Jun 30, 2019 | 1.41 Mn |
| Mar 31, 2019 | 3.89 Mn |
| Dec 31, 2018 | 4.63 Mn |
| Sep 30, 2018 | 10.75 Mn |
| Jun 30, 2018 | 13.35 Mn |
| Mar 31, 2018 | 9.36 Mn |
| Dec 31, 2017 | 10.96 Mn |
| Sep 30, 2017 | 7.00 Mn |
| Jun 30, 2017 | 8.13 Mn |